Urgent boundary: Do not wait for an online PSA explanation if you cannot urinate, have fever with urinary symptoms, heavy bleeding, severe pain or rapid deterioration.
Start with the decision, not the number
Before interpreting PSA, establish why it was tested: screening, follow-up of a prior result, medication-aware monitoring, evaluation after a procedure or part of a broader urinary workup. The same number can lead to different discussions in different contexts.
NCI explains that PSA is produced by normal and malignant prostate cells and can rise for several noncancerous reasons. AUA’s current early-detection guideline uses shared decision-making and risk assessment, including confirmation of a newly elevated result before selected downstream testing. Neither source supports treating an isolated value as a self-diagnosis.
Ten distinct decision pages
Result interpretationPSA Score Meaning: Interpret Context, Not One Cutoff
A PSA result is not a diagnosis and there is no single cutoff that cleanly separates benign prostate conditions from cancer. Meaning comes from the measured value, prior results, age and risk context, prostate size, symptoms, medicines, recent infection or manipulation, testing conditions and what a clinician recommends next.
Open this decisionTest comparisonFree PSA vs Total PSA: What the Ratio Can—and Cannot—Add
Total PSA measures free and protein-bound PSA together; free PSA measures the unbound portion. Percent-free PSA can sometimes refine risk discussions after a total PSA result, but it does not diagnose or exclude cancer, and it should not be interpreted without the total PSA, clinical context, assay information and the reason the test was ordered.
Open this decisionTest comparison and calculationPSA Density vs PSA: Add Prostate Volume Without Pretending to Diagnose
PSA density divides serum PSA by measured prostate volume. It can add anatomical context to a PSA result, especially when clinicians are refining risk, but its reliability depends on accurate and timely inputs. It is not a standalone cancer test and should not be converted into an automatic MRI or biopsy decision.
Open this decisionTrend decisionPSA Velocity: A Trend Is Context, Not a Standalone Trigger
PSA velocity describes how quickly PSA changes over time, often as change per year. A rising pattern deserves clinical review, but current AUA guidance says PSA velocity should not be used as the sole indication for a secondary biomarker, imaging or biopsy. Test conditions, assay variation, infection, medicines and the number and spacing of measurements matter.
Open this decisionNext-step decisionHigh PSA Next Steps: Confirm, Contextualize, Then Escalate Selectively
An elevated PSA does not automatically mean cancer or immediate biopsy. The next discussion may include confirming a newly elevated result, reviewing temporary causes and medicines, estimating overall risk, and selectively using examination, biomarkers, MRI or biopsy. The sequence depends on why PSA was tested, prior results and the person’s broader clinical context.
Open this decisionMedication and testing decisionPSA After Finasteride or Dutasteride: Medication Changes the Baseline
Finasteride and dutasteride can substantially lower serum PSA, including when prostate cancer is present. Interpretation therefore requires the exact drug, dose, reason for use, start date, adherence, prior PSA values and a medication-adjusted clinical plan. Do not apply an online multiplier or stop the medicine without the prescribing clinician.
Open this decisionPost-procedure decisionPSA After TURP or HoLEP: Build a New Post-Procedure Context
PSA commonly changes after TURP or HoLEP because benign prostate tissue is removed, but these procedures do not remove the entire prostate. A post-procedure PSA should be interpreted against the operation performed, pathology report, amount of tissue removed, recovery timeline, medicines and a clinician-defined new baseline—not against expectations after radical prostatectomy.
Open this decisionDiagnostic pathwayTests Before BPH Treatment: Match Each Test to a Decision
Not everyone needs every BPH test. Initial evaluation commonly includes history, physical examination, symptom assessment and urinalysis. Post-void residual, uroflowmetry, prostate imaging, cystoscopy, urodynamics and PSA may be added when their findings could clarify diagnosis, estimate risk or change medication or procedure selection.
Open this decisionDifferential-testing decisionBPH vs Prostate Cancer Testing: Symptoms and PSA Cannot Self-Diagnose the Cause
BPH and prostate cancer are different conditions, but they can coexist and neither urinary symptoms nor PSA can reliably distinguish them alone. BPH, prostatitis, infection and recent prostate manipulation can raise PSA; prostate cancer may cause no early urinary symptoms. Diagnosis requires a clinician to combine history, examination and selected tests.
Open this decision What these pages deliberately refuse to do
- No “PSA number equals cancer” page.
- No age table presented as a diagnosis.
- No automatic finasteride or dutasteride multiplier.
- No velocity, density or free-PSA threshold used as a standalone biopsy recommendation.
- No claim that a negative MRI, biomarker or biopsy creates zero risk.
- No UriSmooth CTA where clinical evaluation is the correct next action.
How the cluster avoids thin and doorway content
Each URL changes the decision being solved: interpreting one result, comparing two laboratory measures, adding prostate volume, analyzing a trend, planning after an elevated result, accounting for medication, resetting context after tissue-removing BPH surgery, selecting pre-treatment tests, or distinguishing benign enlargement from cancer evaluation. Synonyms and number variations stay consolidated on those canonical pages.
All ten drafts remain noindex,follow and excluded from the sitemap. Qualified medical review must confirm every material statement, current guideline and drug-label detail before a page can be considered for indexation. If a page cannot maintain independent value after review, consolidation is the correct action.
Frequently asked questions
1. Does a high PSA mean prostate cancer?
No. Cancer can raise PSA, but so can benign enlargement, inflammation, infection and recent prostate manipulation. The result needs context and sometimes confirmation.
2. Can a normal PSA rule out cancer?
No single PSA value creates zero risk. Screening and diagnostic decisions combine the value with prior results, risk factors and other findings.
3. Should a newly elevated PSA be repeated?
AUA guidance recommends repeating a newly elevated PSA before secondary biomarker testing, imaging or biopsy, while recognizing that timing and exceptions require clinical judgment.
4. What can temporarily raise PSA?
NCI lists infection or inflammation, recent biopsy, vigorous exercise such as cycling and ejaculation among potential influences. Timing should be discussed rather than manipulated without care.
5. Do finasteride and dutasteride change PSA?
Yes. Current prescribing information reports substantial PSA lowering and requires medication-aware interpretation and a new on-treatment context.
6. Is PSA velocity enough to order a biopsy?
No. AUA guidance says velocity should not be used as the sole indication for a secondary biomarker, imaging or biopsy.
7. What is PSA density?
It is serum PSA divided by measured prostate volume. It adds volume context but remains one input, not a diagnosis.
8. What does percent-free PSA add?
It may refine risk in selected situations after a total PSA result, but it cannot confirm or exclude cancer by itself.
9. Does a negative MRI mean no cancer?
No test creates zero risk. MRI findings should be interpreted with PSA, density, history, examination and prior testing.
10. Does everyone need cystoscopy before BPH treatment?
No. Tests should be selected because their findings can clarify diagnosis, anatomy or treatment choice.
11. Will PSA become zero after TURP or HoLEP?
These BPH procedures leave prostate tissue behind, so they should not be confused with radical prostatectomy. A new baseline is clinician-defined.
12. Can UriSmooth replace testing?
No. A supplement cannot diagnose the cause of urinary symptoms, interpret PSA, replace MRI or substitute for biopsy when clinically indicated.
Core sources
Sources checked September 22, 2026. Source organizations do not endorse UriSmooth.